Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Josh Lehrer-Graiwer"'
Autor:
Paul Telfer, Irene Agodoa, Kathleen M. Fox, Laurie Burke, Timothy Mant, Marzena Jurek, Margaret Tonda, Josh Lehrer-Graiwer
Publikováno v:
Hematology Reports, Vol 10, Iss 2 (2018)
For many patients with sickle cell disease (SCD), jaundice is a significant clinical disease manifestation that impacts on patient well-being. We report a case of a patient with SCD and chronic jaundice treated with voxelotor (GBT440), a novel small
Externí odkaz:
https://doaj.org/article/5a6a888f058a4f77855c543547925246
Publikováno v:
Hematology Reports, Vol 8, Iss 3 (2016)
In sickle cell trait (SCT), hemoglobin A (HbA) and S (HbS) are co-expressed in each red blood cell (RBC). While homozygous expression of HbS (HbSS) leads to polymerization and sickling of RBCs resulting in sickle cell disease (SCD) characterized by h
Externí odkaz:
https://doaj.org/article/70541ac8da4246f3947b30f0a6921990
Autor:
Kobina Dufu, Timothy B. Curry, Bruce D. Johnson, Michael J. Joyner, Nicholas E. Vlahakis, Steven C. Chase, Josh Lehrer-Graiwer, Courtney M. Wheatley-Guy, Troy J. Cross, Glenn M. Stewart
Publikováno v:
J Appl Physiol (1985)
Numerous pathophysiological conditions induce hypoxemia-related cardiopulmonary perturbations, decrements in exercise capacity, and debilitating symptoms. Accordingly, this study investigated the efficacy of an allosteric hemoglobin modulator (voxelo
Autor:
Timothy B. Curry, Josh Lehrer-Graiwer, Kobina Dufu, Michael J. Joyner, Bruce D. Johnson, Glenn M. Stewart, Nicholas E. Vlahakis, Steven C. Chase, Troy J. Cross
Publikováno v:
High Alt Med Biol
Stewart, Glenn M., Troy J. Cross, Michael J. Joyner, Steven C. Chase, Timothy Curry, Josh Lehrer-Graiwer, Kobina Dufu, Nicholas E. Vlahakis, and Bruce D. Johnson. Impact of pharmacologically left shifting the oxygen–hemoglobin dissociation curve on
Autor:
Athiwat Hutchaleelaha, Timothy Mant, Elizabeth Allen, Donna Oksenberg, Josh Lehrer-Graiwer, Mira Patel, Carla Washington, Daniel D. Gretler, Vincent Siu
Publikováno v:
British Journal of Clinical Pharmacology
Aims Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb-oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once-daily oral drug to treat sickle cell disease (S
Autor:
Nathan D. Putz, Josh Lehrer-Graiwer, Lorraine B. Ware, Julie A. Bastarache, Qing Xu, Kobina Dufu, Chien-Ming Li, Ciara M. Shaver, Athiwat Hutchaleelaha, Susan M. Majka
Publikováno v:
Journal of Applied Physiology. 124:899-905
Acute respiratory distress syndrome (ARDS) is characterized by lung inflammation and pulmonary edema, leading to arterial hypoxemia and death if the hypoxemia is severe. Strategies to correct hypoxemia have the potential to improve clinical outcomes
Autor:
Kobina Dufu, Josh Lehrer-Graiwer, Ozlem Yalcin, Donna Oksenberg, Nicholas Vlahakis, Zhe Li, Pedro Cabrales, Qing Xu, Athiwat Hutchaleelala, Eilleen S. Y. Ao-ieong
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 313:H381-H391
Adaptation to hypoxia requires compensatory mechanisms that affect O2transport and utilization. Decreased hemoglobin (Hb) O2affinity is considered part of the physiological adaptive process to chronic hypoxia. However, this study explores the hypothe
Autor:
Timothy Mant, Margaret Tonda, Josh Lehrer-Graiwer, Irene Agodoa, Marzena Jurek, Kathleen M. Fox, Laurie B. Burke, Paul Telfer
Publikováno v:
Hematology Reports, Vol 10, Iss 2 (2018)
Hematology Reports
Hematology Reports
For many patients with sickle cell disease (SCD), jaundice is a significant clinical disease manifestation that impacts on patient well-being. We report a case of a patient with SCD and chronic jaundice treated with voxelotor (GBT440), a novel small
Autor:
Kobina, Dufu, Ozlem, Yalcin, Eilleen S Y, Ao-Ieong, Athiwat, Hutchaleelala, Qing, Xu, Zhe, Li, Nicholas, Vlahakis, Donna, Oksenberg, Josh, Lehrer-Graiwer, Pedro, Cabrales
Publikováno v:
American journal of physiology. Heart and circulatory physiology. 313(2)
This study establishes that pharmacological modification of hemoglobin O2 affinity can be a promising and novel therapeutic strategy for the treatment of hypoxic hypoxia and paves the way for the clinical development of molecules that prevent hypoxem
Publikováno v:
Hematology Reports; Volume 8; Issue 3; Pages: 6637
Hematology Reports, Vol 8, Iss 3 (2016)
Hematology Reports
Hematology Reports, Vol 8, Iss 3 (2016)
Hematology Reports
In sickle cell trait (SCT), hemoglobin A (HbA) and S (HbS) are co-expressed in each red blood cell (RBC). While homozygous expression of HbS (HbSS) leads to polymerization and sickling of RBCs resulting in sickle cell disease (SCD) characterized by h